NCT01514448View on ClinicalTrials.gov

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 21, 2012

Primary Completion Date

April 1, 2016

Study Completion Date

April 1, 2016

Conditions
Metastatic Renal Cell Carcinoma (mRCC)
Interventions
DRUG

Everolimus (RAD001)

Everolimus was used as commercially available formulated tablets of 10 mg strength

Trial Locations (13)

30559

Novartis Investigative Site, Hanover

34125

Novartis Investigative Site, Kassel

38440

Novartis Investigative Site, Wolfsburg

39120

Novartis Investigative Site, Magdeburg

42551

Novartis Investigative Site, Velbert

48149

Novartis Investigative Site, Münster

63225

Novartis Investigative Site, Langen

65191

Novartis Investigative Site, Wiesbaden

88214

Novartis Investigative Site, Ravensburg

95028

Novartis Investigative Site, Hof

09130

Novartis Investigative Site, Chemnitz

01307

Novartis Investigative Site, Dresden

04357

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY